Improving cancer immunotherapy by targeting IL-1
Interleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also i...
Guardado en:
Autores principales: | Zhilan Xiao, Shubhra Singh, Manisha Singh |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Taylor & Francis Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fbc895f8725448949ed32765c4489559 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Trial watch: intratumoral immunotherapy
por: Juliette Humeau, et al.
Publicado: (2021) -
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick O, et al.
Publicado: (2021) -
Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
por: Guido Kroemer, et al.
Publicado: (2021) -
Double-edged effects of interferons on the regulation of cancer-immunity cycle
por: Xiao Zhang, et al.
Publicado: (2021) -
The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
por: Xin Xie, et al.
Publicado: (2022)